ArticleAdvanced sensor research2025
A SERS-Based Antibody-Aptamer Sandwich Assay for Extracellular Vesicle-Associated Tau Detection Using Gold Nanoparticles.
Article in Advanced sensor research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Extracellular vesicles (EVs) have emerged as sources of promising, minimally invasive biomarkers for diagnosing and monitoring diseases like Alzheimer's. Using EVs as a source of biomarkers for neurological diseases is highly relevant because they can carry pathogenic proteins, such as tau and amyloid-β, across the blood-brain barrier and can be easily accessed and collected since they are available in almost all biofluids, including blood, urine, and saliva. Here, a bioanalytical antibody-aptamer sandwich assay detection using surface-enhanced Raman spectroscopy (SERS) is developed to quantify the expression of EV-associated tau. Specifically, a gold surface conjugated with antibodies was developed to capture tau protein derived from EVs. Subsequently, adding gold nanoparticles functionalized with SERS probes and aptamers enabled the detection of tau in EVs using SERS. The sensing platform exhibited excellent reproducibility, selectivity, and sensitivity for tau in a broad range of 30 pM-10 nM with a calculated detection limit of 13 pM. Detecting molecular targets within and on the surface of EVs can enable the design of multiplex biosensors for the early diagnosis of multifactorial diseases by simultaneously detecting and quantifying pathogenic proteins, such as amyloid-β and tau in Alzheimer's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.